With swine flu claiming over 470 lives in the country till October-end, the Centre today said the much-awaited Influenza A-H1N1 vaccine to combat the viral disease would be ready by March-April next year.
"Private pharmaceutical companies are in the advanced stage of developing the vaccine and it will be ready by March or April next year," Union Health Minister Ghulam Nabi Azad said here.
He was addressing the 30th convocation of Post Graduate Institute of Medical Education and Research which was attended among others by Prime Minister Manmohan Singh.
Azad said a new department of Health Research had been created in his Ministry which was engaged in promoting and developing some new vaccines.
The Minister said the department had been told to develop low cost testing kits for H1N1 virus and diabetes.
"The road ahead is long and arduous, but together we can achieve the impossible," he said.
As many as 472 people had succumbed to the swine flu in India till October-end with the number of those contracting the infection touching 13,861, according to the Union Health Ministry.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
